Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MAIA Biotechnology, Inc.MAIA · Entity 6919 | Chief Medical Officer | May 31, 2023 | June 05, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MAIA Biotechnology, Inc.
Report date May 31, 2023 · Filed June 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.50 · Expires 2032-05-30 | Direct | 87,495 |
Reported balance
After 2023-05-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-05-31 · Grant · Acquired 87,495 · Balance 87,495 F1: The stock options, granted on May 31, 2023 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options, granted on May 31, 2023 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 31, 2023 Filed Jun 5, 2023 21:23 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 87,495 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001127602-23-017885 · form4.xml · derivative · entry 1 Obrocea Mihail · CIK 0001913265 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,495 Underlying: Common Stock · 87,495 shares Expires 2032-05-30 F1 · derivative.exercise_date: The stock options, granted on May 31, 2023 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 22:06 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 100,000 | $0.00 Strike: $4.10 | $0.00 |
DisclosureSEC source: 0001127602-23-009773 · form4.xml · derivative · entry 1 Obrocea Mihail · CIK 0001913265 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-03-08 F1 · derivative.exercise_date: The stock options, granted on March 8, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary of the date of grant and the remaining options to vest ratably monthly thereafter for 36 months. Read SEC document |
| September 16, 2022 Filed Sep 20, 2022 15:13 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 100,000 | $0.00 Strike: $3.56 | $0.00 |
DisclosureSEC source: 0001127602-22-022737 · form4.xml · derivative · entry 1 Obrocea Mihail · CIK 0001913265 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-09-16 F1 · derivative.exercise_date: The stock options, granted on September 16, 2022 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary of the date of grant and the remaining options to vest ratably monthly thereafter for 36 months. Read SEC document |
| August 01, 2022 Filed Aug 2, 2022 22:35 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 1,000 | $5.00 | $5,000.00 |
DisclosureSEC source: 0000899243-22-027459 · doc4.xml · nonDerivative · entry 1 Obrocea Mihail · CIK 0001913265 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,100 F1 · kind: These shares were purchased by the reporting person in the issuer's initial public offering, which closed on August 1, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.